Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ackermann

Showing results (211-220 of 215) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 215 results.
The New England Journal of Medicine|February 18, 2026
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1Nicholas E Johnson, Li-Jung Tai, Johanna I Hamel, et al.
Journal of Neurology|December 20, 2019
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosisTeresa Coelho, Aaron Yarlas, Marcia Waddington-Cruz, et al.
JAMA Oncology|April 26, 2019
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung CancerFiamma Berner, David Bomze, Stefan Diem, et al.
The New England Journal of Medicine|July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
Muscle & Nerve|January 8, 2017
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trialPeter J Dyck, John C Kincaid, P James B Dyck, et al.
Pageof 22

Showing results (211-220 of 215) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 215 results.
The New England Journal of Medicine|February 18, 2026
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1Nicholas E Johnson, Li-Jung Tai, Johanna I Hamel, et al.
Journal of Neurology|December 20, 2019
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosisTeresa Coelho, Aaron Yarlas, Marcia Waddington-Cruz, et al.
JAMA Oncology|April 26, 2019
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung CancerFiamma Berner, David Bomze, Stefan Diem, et al.
The New England Journal of Medicine|July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
Muscle & Nerve|January 8, 2017
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trialPeter J Dyck, John C Kincaid, P James B Dyck, et al.
Pageof 22